Leppik I E, Lapora J, Loewenson R
Arch Neurol. 1985 Feb;42(2):120-2. doi: 10.1001/archneur.1985.04060020030009.
In a three-year prospective study of patients to whom phenytoin was administered, 26 (8.5%) of 306 patients manifested an erythematous morbiliform rash within three weeks of onset of therapy. Occurrence of the rash was not related to the mode of administration of treatment (loading v maintenance) or initial phenytoin levels. A striking seasonal incidence of the rash was noted: None of the 79 persons who received the initial dose during December to February had a reaction, whereas 13 (20.6%) of 63 persons treated during June to August manifested the rash. For March to May, the rate was 10% (8/88), and for September to November, 6.7% (5/76). Monthly rates were significantly different by chi 2 test.
在一项针对接受苯妥英治疗患者的为期三年的前瞻性研究中,306名患者中有26名(8.5%)在治疗开始后三周内出现了红斑样麻疹样皮疹。皮疹的发生与治疗给药方式(负荷剂量与维持剂量)或初始苯妥英水平无关。注意到皮疹有显著的季节性发病率:12月至2月接受初始剂量的79人中无人出现反应,而6月至8月接受治疗的63人中有13人(20.6%)出现了皮疹。3月至5月的发生率为10%(8/88),9月至11月为6.7%(5/76)。通过卡方检验,每月发病率有显著差异。